RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability
View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
- View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
“Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options. - Our findings here might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study.
- (Photo courtesy of George Naumov)
Mesotheliomas can transform from a less aggressive epithelioid malignancy to a more aggressive sarcomatoid form. - RSO-021 treatment reversed the gene signatures associated with epithelial-to-sarcomatoid transition, including downregulation of hypoxia, glycolysis, and epithelial-to-mesenchymal transition (EMT)-associated genes.